GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello A/S (OCSE:ALK B) » Definitions » Cyclically Adjusted PB Ratio

Alk-Abello A/S (OCSE:ALK B) Cyclically Adjusted PB Ratio : 8.39 (As of Jun. 09, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Alk-Abello A/S Cyclically Adjusted PB Ratio?

As of today (2024-06-09), Alk-Abello A/S's current share price is kr143.70. Alk-Abello A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was kr17.13. Alk-Abello A/S's Cyclically Adjusted PB Ratio for today is 8.39.

The historical rank and industry rank for Alk-Abello A/S's Cyclically Adjusted PB Ratio or its related term are showing as below:

OCSE:ALK B' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.65   Med: 6.56   Max: 12.11
Current: 8.39

During the past years, Alk-Abello A/S's highest Cyclically Adjusted PB Ratio was 12.11. The lowest was 2.65. And the median was 6.56.

OCSE:ALK B's Cyclically Adjusted PB Ratio is ranked worse than
88.35% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs OCSE:ALK B: 8.39

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Alk-Abello A/S's adjusted book value per share data for the three months ended in Mar. 2024 was kr21.190. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr17.13 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alk-Abello A/S Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Alk-Abello A/S's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello A/S Cyclically Adjusted PB Ratio Chart

Alk-Abello A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.24 9.24 11.99 6.01 6.06

Alk-Abello A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.51 4.56 4.78 6.06 7.24

Competitive Comparison of Alk-Abello A/S's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Alk-Abello A/S's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello A/S's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello A/S's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Alk-Abello A/S's Cyclically Adjusted PB Ratio falls into.



Alk-Abello A/S Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Alk-Abello A/S's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=143.70/17.13
=8.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alk-Abello A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Alk-Abello A/S's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=21.19/118.4000*118.4000
=21.190

Current CPI (Mar. 2024) = 118.4000.

Alk-Abello A/S Quarterly Data

Book Value per Share CPI Adj_Book
201406 11.345 99.700 13.473
201409 12.138 99.700 14.415
201412 12.184 99.400 14.513
201503 12.655 100.200 14.954
201506 12.835 100.300 15.151
201509 13.074 100.200 15.449
201512 13.806 99.800 16.379
201603 14.139 100.200 16.707
201606 14.454 100.600 17.011
201609 14.434 100.200 17.056
201612 14.621 100.300 17.259
201703 14.357 101.200 16.797
201706 14.167 101.200 16.575
201709 14.001 101.800 16.284
201712 15.283 101.300 17.863
201803 15.269 101.700 17.776
201806 15.217 102.300 17.612
201809 15.041 102.400 17.391
201812 14.737 102.100 17.090
201903 15.150 102.900 17.432
201906 14.585 102.900 16.782
201909 14.664 102.900 16.873
201912 14.568 102.900 16.762
202003 15.019 103.300 17.214
202006 14.854 103.200 17.042
202009 14.671 103.500 16.783
202012 14.426 103.400 16.519
202103 15.137 104.300 17.183
202106 14.800 105.000 16.689
202109 15.094 105.800 16.892
202112 15.829 106.600 17.581
202203 16.602 109.900 17.886
202206 17.193 113.600 17.919
202209 17.869 116.400 18.176
202212 18.045 115.900 18.434
202303 18.634 117.300 18.809
202306 18.916 116.400 19.241
202309 19.626 117.400 19.793
202312 20.105 116.700 20.398
202403 21.190 118.400 21.190

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alk-Abello A/S  (OCSE:ALK B) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Alk-Abello A/S Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Alk-Abello A/S's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello A/S (OCSE:ALK B) Business Description

Industry
Traded in Other Exchanges
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.

Alk-Abello A/S (OCSE:ALK B) Headlines

No Headlines